RxDoctor Payments Data

Terri Hancock

Nurse Practitioner · Salt Lake City, UTNPI 1245510536

Payments from drug & device makers

$1,462in general payments, 2019–2025

Across 28 payments — averaging $52.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$541
  • AbbVie$378
  • Boston Scientific$174
  • Abbott$170
  • Novo Nordisk$122
  • Novartis$77

What the payments were for

  • Food & beverage$1,462100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,462 in reported general payments places this provider in the 80th percentile of 979 nurse practitioner providers in Utah.

See all nurse practitioner providers in Utah

Medicare billing

Part B allowed, 2024
$30,469
Medicare patients
151
Services billed
378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban114$147,432
FarxigaDapagliflozin Propanediol150$146,891
JardianceEmpagliflozin77$72,022
EntrestoSacubitril/Valsartan32$38,591
XareltoRivaroxaban25$35,208
OzempicSemaglutide25$23,172
Eplerenone45$6,558
Praluent PenAlirocumab13$6,163
Torsemide186$5,357
Spironolactone493$4,884
Atorvastatin Calcium263$2,540
Metoprolol Succinate166$2,062
Rosuvastatin Calcium183$1,963
Furosemide310$1,763
Carvedilol127$1,453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$77$38,59132 claims
Novo NordiskOzempic$122$23,17225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 979 nurse practitioner providers in Utah.

Other nurse practitioner in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →